Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 2/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8512456 | 0.80 | ESR2 (0.40) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8514392 | 0.80 | CHRNB2 (0.43) | KMT2ATDP1 | |
| SCHEMBL2408324 | 0.80 | CHRNB2 (0.43) | KMT2ATDP1 | |
| SCHEMBL30144812 | 0.78 | KDM4E (0.42) | ESR2KDM4EGLAHTTKMT2A | |
| SCHEMBL595630 | 0.78 | KDM4E (0.42) | ESR2KDM4EGLAHTTKMT2A | |
| SCHEMBL717834 | 0.77 | ESR2 (0.50) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25048716 | 0.76 | PDE4A (0.48) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL3703416 | 0.76 | PDE4A (0.48) | ESR2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL25356663 | 0.74 | KDM4E (0.51) | KDM4EGLAHTTKMT2ASMN1; SMN2 | |
| SCHEMBL16690791 | 0.74 | MAPK1 (0.41) | KDM1AMAOAMAOBSPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267516-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-10-10 | — | — | US | claimed |
| EP-2643298-A1 | SUBSTITUTED CYCLOPENTYL - AZINES AS CASR- ACTIVE COMPOUNDS | Leo Pharma A/S (DK) | 2013-10-02 | — | — | EP | claimed |
| CN-103228629-A | Substituted cyclopentyl -azines as CaSR- active compounds | LEO PHARMA AS | 2013-07-31 | — | — | CN | claimed |
| WO-2012069402-A1 | SUBSTITUTED CYCLOPENTYL - AZINES AS CASR- ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2012-05-31 | — | — | WO | claimed |
| US-20130267516-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-10-10 | — | — | US | disclosed |
| US-20130267516-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-10-10 | — | — | US | disclosed |
| US-20130267516-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-10-10 | — | — | US | disclosed |
| EP-2643298-A1 | SUBSTITUTED CYCLOPENTYL - AZINES AS CASR- ACTIVE COMPOUNDS | Leo Pharma A/S (DK) | 2013-10-02 | — | — | EP | disclosed |
| CN-103228629-A | Substituted cyclopentyl -azines as CaSR- active compounds | LEO PHARMA AS | 2013-07-31 | — | — | CN | disclosed |
| WO-2012069402-A1 | SUBSTITUTED CYCLOPENTYL - AZINES AS CASR- ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2012-05-31 | — | — | WO | disclosed |
| WO-2012069402-A1 | SUBSTITUTED CYCLOPENTYL - AZINES AS CASR- ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267516-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | CASR, PTH1R, CALCR | ESR2 400/4885HCAR2 62/4885PDE4A 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.